直接作用抗病毒治疗丙型肝炎病毒后发生的肝细胞癌：临近尾声的争议。
Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end.
机构信息
Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, St. Spiridon Emergency Hospital, Iasi 700115, Romania.
出版信息
World J Gastroenterol. 2020 Nov 21;26(43):6770-6781. doi: 10.3748/wjg.v26.i43.6770.
Abstract
Direct acting antivirals (DAAs) have revolutionized the treatment of hepatitis C virus (HCV) infection, achieving high rates (≥ 95%) of sustained virological response, with a good safety profile and high compliance rates. Consequently, it had been expected that viral clearance will reduce morbidity and mortality rates, as well as the risk of hepatocellular carcinoma (HCC). However, since 2016, concerns have been raised over an unexpected high rate of HCC occurrence and recurrence after DAA therapy, which led to an avalanche of studies with contradictory results. We aimed to review the most recent and relevant articles regarding the risk of HCC after DAA treatment and identify the associated risk factors.
摘要
直接作用抗病毒药物（DAAs）彻底改变了丙型肝炎病毒（HCV）感染的治疗方法，实现了高持续病毒学应答率（≥95%），具有良好的安全性和高依从性。因此，人们曾预计病毒清除将降低发病率和死亡率，以及肝癌（HCC）的风险。然而，自 2016 年以来，人们对 DAA 治疗后 HCC 发生率和复发率的意外升高表示担忧，这导致了大量研究，但结果却相互矛盾。我们旨在回顾与 DAA 治疗后 HCC 风险相关的最新和最相关的文章，并确定相关的危险因素。
相似文献
1
Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end.直接作用抗病毒治疗丙型肝炎病毒后发生的肝细胞癌：临近尾声的争议。
World J Gastroenterol. 2020 Nov 21;26(43):6770-6781. doi: 10.3748/wjg.v26.i43.6770.
2
Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.治疗结束时的血清甲胎蛋白水平是丙型肝炎病毒直接抗病毒治疗清除后一年以上发生肝细胞癌的有用预测指标。
J Viral Hepat. 2022 Jan;29(1):35-42. doi: 10.1111/jvh.13625. Epub 2021 Oct 27.
3
Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.直接作用抗病毒药物治疗的丙型肝炎病毒感染者肝细胞癌复发风险。
Dig Dis Sci. 2019 Nov;64(11):3328-3336. doi: 10.1007/s10620-019-05641-3. Epub 2019 Apr 30.
4
Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.血清血管生成素 2 预测丙型肝炎直接抗病毒治疗后肝细胞癌的发生和复发。
Viruses. 2023 Jan 7;15(1):181. doi: 10.3390/v15010181.
5
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.直接作用抗病毒药物治疗早期肝细胞癌后可改善 HCV 肝硬化患者的生存。
J Hepatol. 2019 Aug;71(2):265-273. doi: 10.1016/j.jhep.2019.03.027. Epub 2019 Apr 6.
6
The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.直接作用抗病毒药物对根治性治疗后丙型肝炎病毒相关肝细胞癌的影响。
Invest New Drugs. 2020 Feb;38(1):202-210. doi: 10.1007/s10637-019-00870-9. Epub 2019 Nov 8.
7
The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.直接作用抗病毒治疗对丙型肝炎病毒相关早期肝细胞癌根治性切除术后复发风险的影响。
Medicina (Kaunas). 2022 Feb 9;58(2):259. doi: 10.3390/medicina58020259.
8
Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.直接作用抗病毒药物对多次复发的丙型肝炎病毒相关复发性肝细胞癌患者的疗效。
J Viral Hepat. 2021 Nov;28(11):1597-1603. doi: 10.1111/jvh.13579. Epub 2021 Sep 6.
9
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.直接作用抗病毒药物与慢性丙型肝炎相关肝细胞癌：喜忧参半。
World J Gastroenterol. 2018 Jun 28;24(24):2582-2595. doi: 10.3748/wjg.v24.i24.2582.
10
Chronic Hepatitis C: Advances in Therapy and the Remaining Challenges.慢性丙型肝炎：治疗进展及尚存挑战。
Med Clin North Am. 2023 May;107(3):423-433. doi: 10.1016/j.mcna.2023.01.001. Epub 2023 Feb 20.
引用本文的文献
1
Regulation of viral hepatitis by N6-methyladenosine RNA methylation.N6-甲基腺苷RNA甲基化对病毒性肝炎的调控
Emerg Microbes Infect. 2025 Dec;14(1):2544726. doi: 10.1080/22221751.2025.2544726. Epub 2025 Aug 17.
2
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?直接作用抗病毒药物治疗慢性丙型肝炎感染与肝细胞癌的发生/复发：这仍然重要吗？
Viruses. 2024 Dec 10;16(12):1899. doi: 10.3390/v16121899.
3
Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs).使用直接抗病毒药物（DAAs）根除慢性丙型肝炎后肝硬化患者的长期预后
J Hepatocell Carcinoma. 2024 Oct 30;11:2115-2132. doi: 10.2147/JHC.S475810. eCollection 2024.
4
Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination.抗病毒治疗后患者的随访丢失是消除 HCV 的另一个障碍。
BMC Med. 2024 Oct 23;22(1):486. doi: 10.1186/s12916-024-03699-z.
5
Impacts of smoking on alcoholic liver disease: a nationwide cohort study.吸烟对酒精性肝病的影响：一项全国性队列研究。
Front Public Health. 2024 Aug 7;12:1427131. doi: 10.3389/fpubh.2024.1427131. eCollection 2024.
6
Increased prevalence but decreased survival of nonviral hepatocellular carcinoma compared to viral hepatocellular carcinoma in recent ten years.近十年来，非病毒性肝细胞癌的发病率增加，但生存率却低于病毒性肝细胞癌。
Sci Rep. 2024 Apr 20;14(1):9068. doi: 10.1038/s41598-024-59668-2.
7
Long-Term Survival and Cancer Risk in the Hepatitis C Virus-Infected Patients After Antiviral Treatment: A Nationwide Cohort Study.抗病毒治疗后丙型肝炎病毒感染患者的长期生存及癌症风险：一项全国性队列研究
J Cancer. 2024 Jan 1;15(1):113-125. doi: 10.7150/jca.87259. eCollection 2024.
8
Bioinformatics analysis of multi-epitope peptide vaccines against Hepatitis C virus: a molecular docking study.丙型肝炎病毒多表位肽疫苗的生物信息学分析：一项分子对接研究
J Genet Eng Biotechnol. 2023 Nov 14;21(1):117. doi: 10.1186/s43141-023-00583-w.
9
Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma.不可切除肝细胞癌的潜在分子靶向治疗。
Curr Oncol. 2023 Jan 18;30(2):1363-1380. doi: 10.3390/curroncol30020105.
10
ADAM10 Gene Polymorphism and Its Relationship to Hepatocellular Carcinoma in Egyptian HCV Patients Receiving Direct-Acting Antiviral Therapies (DAAs).ADAM10 基因多态性及其与接受直接抗病毒治疗（DAAs）的埃及 HCV 患者肝细胞癌的关系。
Asian Pac J Cancer Prev. 2023 Jan 1;24(1):149-155. doi: 10.31557/APJCP.2023.24.1.149.
本文引用的文献
1
Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma.直接作用抗病毒疗法治疗丙型肝炎相关肝细胞癌的影响。
PLoS One. 2020 May 22;15(5):e0233212. doi: 10.1371/journal.pone.0233212. eCollection 2020.
2
Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis.与未治疗丙型肝炎相比，直接作用抗病毒药物降低肝细胞癌复发风险的荟萃分析。
Ann Gastroenterol. 2020 May-Jun;33(3):293-298. doi: 10.20524/aog.2020.0470. Epub 2020 Mar 27.
3
Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection.丙型肝炎病毒感染患者直接作用抗病毒治疗后肝细胞癌发生的性别差异。
J Med Virol. 2020 Dec;92(12):3507-3515. doi: 10.1002/jmv.25984. Epub 2020 May 17.
4
Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.未定义/非恶性肝结节与 HCV 相关肝硬化 DAA 治疗患者 HCC 的早期发生相关。
J Hepatol. 2020 Sep;73(3):593-602. doi: 10.1016/j.jhep.2020.03.030. Epub 2020 Mar 31.
5
Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients.直接作用抗病毒药物和基于干扰素的疗法对慢性丙型肝炎患者肝细胞癌风险的影响。
Future Oncol. 2020 Apr;16(11):675-686. doi: 10.2217/fon-2019-0845. Epub 2020 Mar 30.
6
Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study.直接抗病毒治疗清除丙型肝炎病毒后肝细胞癌发生预测的简易评分系统：全香川县肝病研究组研究
Oncol Lett. 2020 Mar;19(3):2205-2212. doi: 10.3892/ol.2020.11341. Epub 2020 Jan 23.
7
The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk.直接作用抗病毒药物和基于干扰素的 HCV 治疗的 SVR 对肝细胞癌风险的影响。
J Viral Hepat. 2020 Aug;27(8):781-793. doi: 10.1111/jvh.13295. Epub 2020 Apr 17.
8
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.在 TOPAZ-I 和 TOPAZ-II 试验中，接受奥比他韦/帕利瑞韦/利托那韦+达萨布韦±利巴韦林治疗的 HCV 基因 1 型感染患者的长期安全性和疗效结果。
J Viral Hepat. 2020 May;27(5):497-504. doi: 10.1111/jvh.13261. Epub 2020 Feb 17.
9
Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment.直接抗病毒药物实现的持续病毒学应答可降低丙肝相关肝细胞癌根治性治疗后的复发风险。
Mol Clin Oncol. 2020 Feb;12(2):111-116. doi: 10.3892/mco.2019.1956. Epub 2019 Nov 29.
10
Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents.直接作用抗病毒药物治疗的 HCV 患者的肝细胞癌长期风险。
Hepatology. 2020 Jan;71(1):44-55. doi: 10.1002/hep.30823. Epub 2019 Aug 19.
Zotero 插件